Английская Википедия:Glecaprevir

Материал из Онлайн справочника
Версия от 17:48, 14 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{short description|Chemical compound}} {{Drugbox | IUPAC_name = (3a''R'',7''S'',10''S'',12''R'',21''E'',24a''R'')-7-''tert''-Butyl-''N''-{(1''R'',2''R'')-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1''H'',10''H''-9,12-methanocyclopenta[18,19] [1,10,17,3,6]trioxadiazacyclonon adecino[1...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Glecaprevir (INN,[1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.[2]

On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.[3] In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.[4]

See also

References

Шаблон:Reflist

Шаблон:RNA antivirals


Шаблон:Antiinfective-drug-stub

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ Шаблон:Cite web
  2. ↑ Шаблон:Cite journal
  3. ↑ Шаблон:Cite news
  4. ↑ Шаблон:Cite web
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Glecaprevir&oldid=14957976